Validation of a Ligand Binding Assay Using Dried Blood Spot Sampling
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 1
Abstract
Dried blood spots (DBS) technology has been introduced as a microsampling alternative to traditional plasma or serum sampling for pharmacokinetics or toxicokinetics evaluation. The application of DBS has been established for many small molecule drugs at discovery, nonclinical, and clinical stages. However, the application of DBS for large molecule therapeutics development is not yet well-established. This article describes the method validation of a ligand binding assay (LBA) for DBS sampling of a therapeutic monoclonal antibody—AMG 162 (Denosumab). The original serum LBA was modified for the DBS method. A fit-for-purpose method validation was performed to evaluate accuracy and precision, selectivity, dilutional linearity, and stability. In addition, the parameters relevant to DBS, such as spot volume, extraction recovery, whole blood stability, and hematocrit effects, were evaluated. The validation results demonstrated assay robustness with inter-assay precision of ≤19%, inter-assay accuracy of ≤9%, and total error of ≤24%. Selectivity, extraction recovery, dilutional linearity, and stability were demonstrated. The validation results revealed some limitations of the possible effect of blood hematocrit on therapeutic concentration measurements and the caution required using whole blood for standards and quality controls preparation. This is the first article to describe a thorough method validation of an LBA using DBS for a therapeutic monoclonal antibody. The lessons learned can serve as a model process for future method validation of other LBAs for large molecule therapeutics or biomarkers using the DBS sampling method.
Authors and Affiliations
Daniel Burns, Laura Brunner, Surendran Rajendran, Beth Johnson, Mark Ma, Jin Wang
Keywords
Related Articles
- EP ID EP681754
- DOI 10.1208/s12248-012-9430-x
- Views 111
- Downloads 0
Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin
The online version of this article (doi:10.1208/s12248-015-9848-z) contains supplementary material, which is available to authorized users.
Impact-Insertion Applicator Improves Reliability of Skin Penetration by Solid Microneedle Arrays
In this study, high-density arrays (576 microneedles on a 5 × 5-mm backplate, gifted by Bosch, Germany, Stuttgart) with a microneedle length of 200 μm were used (Fig. 1 )....
Calculations for Adjusting Endogenous Biomarker Levels During Analytical Recovery Assessments for Ligand-Binding Assay Bioanalytical Method Validation
It is often necessary to adjust for detectable endogenous biomarker levels in spiked validation samples (VS) and in selectivity determinations during bioanalytical method validation for ligand-binding assays (LBA) with a...
Glial–Neuronal Interactions—Implications for Plasticity and Drug Addiction
Among neuroscientists, astrocytes have for long played Cinderella to their neuron stepsisters. While the importance of glia in regulating brain activity was predicted by Ramon y Cajal more than a century ago (Garcia-Mari...
Completeness Assessment of Type II Active Pharmaceutical Ingredient Drug Master Files under Generic Drug User Fee Amendment: Review Metrics and Common Incomplete Items
Under the Generic Drug User Fee Amendments (GDUFA) of 2012, Type II active pharmaceutical ingredient (API) drug master files (DMFs) must pay a user fee and pass a Completeness Assessment (CA) before they can be reference...